Overexpression of β-klotho in adipose tissue sensitizes male mice to endogenous FGF21 and provides protection from diet-induced obesity

Endocrinology

Volumn 157, Issue 4, 2016, Pages 1467-1480

  Samms, Ricardo J ^a   Cheng, Christine C ^a   Kharitonenkov, Alexei ^a,b   Gimeno, Ruth E ^a   Adams, Andrew C ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 21; KLB PROTEIN, MOUSE; MEMBRANE PROTEIN;

ADIPOSE TISSUE; ADVERSE EFFECTS; ANIMAL; BLOOD; BODY WEIGHT; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HUMAN; LIPID DIET; LIVER; MALE; METABOLISM; OBESITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; WESTERN BLOTTING;

ADIPOSE TISSUE; ANIMALS; BLOTTING, WESTERN; BODY WEIGHT; DIET, HIGH-FAT; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION; HUMANS; LIVER; MALE; MEMBRANE PROTEINS; MICE, TRANSGENIC; OBESITY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84964455482     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2015-1722     Document Type: Article

References (59)

1. Markan KR, Potthoff MJ. Metabolic fibroblast growth factors (FGFs): mediators of energy homeostasis [published online ahead of print September 30, 2015]. Semin Cell Dev Biol. doi:10.1016/j.semcdb. 2015.09.021.
2. Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev. 2012;26:312-324.
3. Kharitonenkov A, Adams AC. Inventing new medicines: the FGF21 story. Mol Metab. 2014;3:221-229.
4. Kurosu H, Choi M, Ogawa Y, et al. Tissue-specific expression of β klotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem. 2007;282:26687-26695.
5. SuzukiM,Uehara Y, Motomura-Matsuzaka K, et al. β Klotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol. 2008;22:1006-1014.
6. Kharitonenkov A, Dunbar JD, Bina HA, et al. FGF-21/FGF-21 receptor interaction and activation is determined by β klotho. J Cell Physiol. 2008;215:1-7.
7. Katafuchi T, Esterházy D, Lemoff A, et al. Detection of FGF15 in plasma by stable isotope standards and capture by anti-peptide antibodiesandtargetedmassspectrometry. CellMetab.2015;21:898-904.
8. Fon Tacer K, Bookout AL, Ding X, et al. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol. 2010;24:2050-2064.
9. Adams AC, Cheng CC, Coskun T, Kharitonenkov A. FGF21 requires β klotho to act in vivo. PLoS One. 2012;7:e49977.
10. Ding X, Boney-Montoya J, Owen BM, et al. β Klotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab. 2012;16:387-393.
11. Owen BM, Ding X, Morgan DA, et al. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab. 2014;20:670-677.
12. Bookout AL, de Groot MH, Owen BM, et al. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat Med. 2013;19:1147-1152.
13. Owen BM, Bookout AL, Ding X, et al. FGF21 contributes to neuroendocrine control of female reproduction. Nat Med. 2013;19: 1153-1156.
14. Samms RJ, Fowler MJ, Cooper S, et al. Photoperiodic regulation of FGF21 production in the Siberian hamster. Horm Behav. 2014;66: 180-185.
15. So WY, Cheng Q, Chen L, et al. High glucose represses β-klotho expression and impairs fibroblast growth factor 21 action in mouse pancreatic islets: involvement of peroxisome proliferator-activated receptor γ signaling. Diabetes. 2013;62:3751-3759.
16. Ribas F, Villarroya J, Hondares E, Giralt M, Villarroya F. FGF21 expression and release in muscle cells: involvement of MyoD and regulation by mitochondria-driven signalling. Biochem J. 2014;463:191-199.
17. Hondares E, Iglesias R, Giralt A, et al. Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem. 2011;286:12983-12990.
18. Markan KR, Naber MC, Ameka MK, et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes. 2014;63:4057-4063.
19. Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology. 2009;150:4931-4940.
20. Dushay J, Chui PC, Gopalakrishnan GS, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology. 2010;139:456-463.
21. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPAR α and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007;5:426-437.
22. Laeger T, Henagan TM, Albarado DC, et al. FGF21 is an endocrine signal of protein restriction. J Clin Invest. 2014;124:3913-3922.
23. Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response byPPAR α-mediated induction of fibroblast growth factor 21. Cell Metab. 2007;5:415-425.
24. Liang Q, Zhong L, Zhang J, et al. FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting. Diabetes. 2014;63:4064-4075.
25. Luo Y, McKeehan WL. Stressed liver and muscle call on adipocytes with FGF21. Front Endocrinol. 2013;4:194.
26. Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 2010;59:2781-2789.
27. Hale C, Chen MM, Stanislaus S, et al. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. Endocrinology. 2012;153:69-80.
28. Romero-Calvo I, Ocón B, Martínez-Moya P, et al. Reversible Ponceau staining as a loading control alternative to actin in Western blots. Anal Biochem. 2010;401:318-320.
29. Martens K, Bottelbergs A, Baes M. Ectopic recombination in the central and peripheral nervous system by aP2/FABP4-Cre mice: implications for metabolism research. FEBS Lett. 2010;584:1054-1058.
30. Vandanmagsar B, Youm YH, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011;17:179-188.
31. Dixit VD. Adipose tissue macrophages are innate to the immunological awareness of adipose tissue. Diabetes. 2013;62:2656-2658.
32. Hill AA, Reid Bolus W, Hasty AH. A decade of progress in adipose tissue macrophage biology. Immunol Rev. 2014;262:134-152.
33. Yu Y, Zhang XH, Ebersole B, Ribnicky D, Wang ZQ. Bitter melon extract attenuating hepatic steatosis may be mediated by FGF21 and AMPK/Sirt1 signaling in mice. Sci Rep. 2013;3:3142.
34. Zhang J, Li Y. Fibroblast growth factor 21, the endocrine FGF pathway and novel treatments for metabolic syndrome. Drug Discov Today. 2014;19:579-589.
35. Kharitonenkov A, DiMarchi R. FGF21 revolutions: recent advances illuminating FGF21 biology and medicinal properties. Trends Endocrinol Metab. 2015;26:608-617.
36. VeniantMM,Hale C, Helmering J, et al.FGF21promotes metabolic homeostasis via white adipose and leptin in mice. PLoS One. 2012; 7:e40164.
37. Holland WL, Adams AC, Brozinick JT, et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 2013;17:790-797.
38. Emanuelli B, Vienberg SG, Smyth G, et al. Interplay between FGF21 and insulin action in the liver regulates metabolism. J Clin Invest. 2014;124:515-527.
39. Adams AC, Yang C, Coskun T, et al. The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue. Mol Metab. 2012;2:31-37.
40. Fisher FM, Estall JL, Adams AC, et al. Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. Endocrinology. 2011;152:2996-3004.
41. Samms RJ, Smith DP, Cheng CC, et al. Discrete aspects of FGF21 in vivo pharmacology do not require UCP1. Cell Rep. 2015;11:991-999.
42. Reitman ML. FGF21: a missing link in the biology of fasting. Cell Metab. 2007;5:405-407.
43. Gaich G, Chien JY, Fu H, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013;18:333-340.
44. Storlien L, Oakes ND, Kelley DE. Metabolic flexibility. Proc Nutr Soc. 2004;63:363-368.
45. MyersMG,CowleyMA,Münzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol. 2008;70:537-556.
46. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106:473-481.
47. Gallego-Escuredo JM, Gomez-Ambrosi J, Catalan V, et al. Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients. Int J Obes (Lond). 2015;39:121-129.
48. Coskun T, Bina HA, Schneider MA, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology. 2008;149:6018-6027.
49. Xu J, Lloyd DJ, Hale C, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes. 2009;58:250-259.
50. Chau MD, Gao J, Yang Q, Wu Z, Gromada J. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPKSIRT1-PGC-1α pathway. Proc Natl Acad Sci USA. 2010;107: 12553-12558.
51. Véniant MM, Sivits G, Helmering J, et al. Pharmacologic effects of FGF21 are independent of the "browning" of white adipose tissue. Cell Metab. 2015;21:731-738.
52. Ukropec J, Anunciado RV, Ravussin Y, Kozak LP. Leptin is required for uncoupling protein-1-independent thermogenesis during cold stress. Endocrinology. 2006;147:2468-2480.
53. Anunciado-Koza R, Ukropec J, Koza RA, Kozak LP. Inactivation of UCP1 and the glycerol phosphate cycle synergistically increases energy expenditure to resist diet-induced obesity. J Biol Chem. 2008; 283:27688-27697.
54. Lin Z, Pan X, Wu F, et al. Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory elementbinding protein-2 and induction of adiponectin in mice. Circulation. 2015;131:1861-1871.
55. ShangW,YuX,WangH, et al. Fibroblast growth factor 21 enhances cholesterol efflux in THP-1 macrophage-derived foam cells. Mol Med Rep. 2015;11:503-508.
56. Lin XL, He XL, Zeng JF, et al. FGF21 increases cholesterol efflux by upregulating ABCA1 through the ERK1/2-PPARγ-LXRα pathway in THP1 macrophage-derived foam cells.DNA Cell Biol. 2014;33:514-521.
57. Wu X, Ge H, Baribault H, et al. Dual actions of fibroblast growth factor 19 on lipid metabolism. J Lipid Res. 2013;54:325-332.
58. Díaz-Delfín J, Hondares E, Iglesias R, Giralt M, Caelles C, Villarroya F. TNF-α represses β-klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology. 2012;153:4238-4245.
59. Adams AC, Coskun T, Cheng CC, O Farrell LS, Dubois SL, Kharitonenkov A. Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones. Mol Metab. 2013;2: 205-214.